Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 19/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27600213 | 0.72 | DPP4 (0.36) | DPP4KCNH2CHRM1CHRM2CHRM3 | |
| SCHEMBL554964 | 0.67 | DPP4 (0.39) | DPP4KCNH2CHRM1CHRM2CHRM3 | |
| SCHEMBL27600222 | 0.66 | TSHR (0.39) | DPP4KCNH2 | |
| SCHEMBL2997185 | 0.65 | DPP4 (0.40) | DPP4KCNH2CHRM1CHRM2CHRM3 | |
| SCHEMBL28749952 | 0.64 | DPP4 (0.40) | DPP4KCNH2CHRM1CHRM2CHRM3 | |
| SCHEMBL28749946 | 0.63 | DPP4 (0.43) | DPP4KCNH2CHRM1CHRM2CHRM3 | |
| SCHEMBL2963847 | 0.62 | DPP4 (0.34) | DPP4KCNH2CHRM1CHRM2CHRM3 | |
| SCHEMBL27600539 | 0.62 | DPP4 (0.42) | DPP4KCNH2CHRM1CHRM2CHRM3 | |
| SCHEMBL27600224 | 0.62 | DPP4 (0.38) | DPP4KCNH2CHRM1CHRM2CHRM3 | |
| SCHEMBL27582935 | 0.62 | DPP4 (0.40) | DPP4KCNH2CHRM1CHRM2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020198205-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198205-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | DPP4 1/4885KCNH2 3381/4885CHRM1 805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.